MDNA Fundamental Analysis - MEDICENNA THERAPEUTICS CORP

Fundamental Rating

Overall MDNA gets a fundamental rating of 1 out of 10. We evaluated MDNA against 24 industry peers in the Biotechnology industry. While MDNA seems to be doing ok healthwise, there are quite some concerns on its profitability. MDNA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MDNA has reported negative net income.

In the past year MDNA has reported a negative cash flow from operations.

In the past 5 years MDNA always reported negative net income.

MDNA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MDNA has a Return On Assets of -76.58%. This is comparable to the rest of the industry: MDNA outperforms 58.33% of its industry peers.

MDNA has a Return On Equity of -134.89%. This is in the better half of the industry: MDNA outperforms 70.83% of its industry peers.

		Industry Rank	Sector Rank
ROA	-76.58%
ROE	-134.89%
ROIC	N/A

ROA(3y)-67.42%

ROA(5y)-67.89%

ROE(3y)-195.49%

ROE(5y)-148.03%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MDNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for MDNA has been increased compared to 1 year ago.

The number of shares outstanding for MDNA has been increased compared to 5 years ago.

MDNA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -7.00, we must say that MDNA is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -7.00, MDNA perfoms like the industry average, outperforming 54.17% of the companies in the same industry.

A Debt/Equity ratio of 0.01 indicates that MDNA is not too dependend on debt financing.

MDNA has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. MDNA outperforms 87.50% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-7

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 4.01 indicates that MDNA has no problem at all paying its short term obligations.

MDNA's Current ratio of 4.01 is fine compared to the rest of the industry. MDNA outperforms 75.00% of its industry peers.

MDNA has a Quick Ratio of 4.01. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.

MDNA has a Quick ratio of 4.01. This is in the better half of the industry: MDNA outperforms 75.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.01
Quick Ratio	4.01

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.05%, which is quite impressive.

EPS 1Y (TTM)54.05%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-20%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

MDNA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -65.36% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-59.8%

EPS Next 2Y-72.97%

EPS Next 3Y-65.36%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MDNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDNA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MDNA's earnings are expected to decrease with -65.36% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-72.97%

EPS Next 3Y-65.36%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MDNA!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDICENNA THERAPEUTICS CORP

TSX:MDNA (12/24/2025, 7:00:00 PM)

0.94

-0.02 (-2.08%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-11 2025-11-11/amc

Earnings (Next)02-11 2026-02-11

Inst Owners6.32%

Inst Owner ChangeN/A

Ins Owners14.23%

Ins Owner ChangeN/A

Market Cap78.41M

Revenue(TTM)N/A

Net Income(TTM)-13.81M

Analysts82

Price Target4.26 (353.19%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-5.27%

Min EPS beat(2)-17.65%

Max EPS beat(2)7.12%

EPS beat(4)2

Avg EPS beat(4)29.8%

Min EPS beat(4)-17.65%

Max EPS beat(4)132.68%

EPS beat(8)5

Avg EPS beat(8)-11.92%

EPS beat(12)9

Avg EPS beat(12)6.23%

EPS beat(16)13

Avg EPS beat(16)12.81%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)19.23%

PT rev (3m)60.08%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)7.84%

EPS NY rev (3m)4.08%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-100%

Revenue NY rev (3m)-100%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	7.66
P/tB	7.69
EV/EBITDA	N/A

EPS(TTM)-0.17

EYN/A

EPS(NY)-0.45

Fwd EYN/A

FCF(TTM)-0.2

FCFYN/A

OCF(TTM)-0.2

OCFYN/A

SpS0

BVpS0.12

TBVpS0.12

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-76.58%
ROE	-134.89%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-67.42%

ROA(5y)-67.89%

ROE(3y)-195.49%

ROE(5y)-148.03%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.01
Quick Ratio	4.01
Altman-Z	-7

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)54.05%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-20%

EPS Next Y-59.8%

EPS Next 2Y-72.97%

EPS Next 3Y-65.36%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-18.93%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-27.69%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-27.69%

OCF growth 3YN/A

OCF growth 5YN/A

MEDICENNA THERAPEUTICS CORP / MDNA.CA FAQ

Can you provide the ChartMill fundamental rating for MEDICENNA THERAPEUTICS CORP?

ChartMill assigns a fundamental rating of 1 / 10 to MDNA.CA.

What is the valuation status for MDNA stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDICENNA THERAPEUTICS CORP (MDNA.CA). This can be considered as Overvalued.

What is the profitability of MDNA stock?

MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a profitability rating of 1 / 10.

MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MEDICENNA THERAPEUTICS CORP / MDNA.CA FAQ

Can you provide the ChartMill fundamental rating for MEDICENNA THERAPEUTICS CORP?

What is the valuation status for MDNA stock?

What is the profitability of MDNA stock?